Concussion Assessment and Monitoring with Eye Movement Biomarkers
Clinical highlights – November 2025 neuroClues® has officially received its CE-marking as a Class IIa medical device, av …
Instability of Neurological Diagnosis
Clinical highlights – June 2025 neuroClues® has officially received its CE-marking as a Class IIa medical device, availa …
Reliability of Oculomotor Biomarkers
Clinical highlights – May 2025 neuroClues® has officially received its CE-marking as a Class IIa medical device, availab …
Exploring Anti-Saccades and Frontal Lobe Function
Clinical highlights – April 2025 neuroClues has officially received its CE-marking as a Class IIa medical device, availa …
Neural Pathways of Voluntary and Reflexive Saccades
Clinical highlights – March 2025 In this article, we explore the differences between voluntary and reflexive saccades, t …
Oculomotor Biomarkers Recorded on 50 Patients with neuroClues®, now CE-Marked!
Clinical highlights – February 2025 This month’s newsletter is eye-opening. As you may know, neuroClues® has officially …
.png)
Reference Oculomotor Ranges in Eye Tracking with NeuroClues
Clinical highlights – December 2024 For this last newsletter of 2024, we wanted to share for the first time an exclusive …
Eye Movements: A Key to Supporting Pharmaceutical Research
Clinical highlights – November 2024 This month’s newsletter will highlight recent studies demonstrating how eye movement …
Clinical highlights: Multiple Sclerosis (MS)
Clinical highlights – August 2024 We are excited to share insights into the potential of eye tracking. Every month, we k …
Clinical highlights: Alzheimer’s Disease (AD)
Clinical highlights – July 2024 We are thrilled to inform you about the clinical benefits of eye tracking. Every month, …
